A 2026 prospective German aneurysm cohort found risky alcohol use in 4.6% of 954 intracranial aneurysm patients, and that exposure carried 2.00x higher adjusted odds of aneurysm rupture plus 3.26x higher adjusted odds of clinically severe aneurysmal subarachnoid hemorrhage. Research Highlights Risky alcohol was the main signal: drinking above the study threshold was independently associated …
Semaglutide is not close to being an approved cocaine-use-disorder medication, but a 2026 rat study gives the idea a more demanding preclinical test than ordinary self-administration experiments. After 5 days of treatment, rats shifted away from cocaine choice without losing total operant responding, which separates the result from a broad appetite-suppression artifact. Research Highlights Semaglutide …
A 2026 cross-species metabolism study found that eutylone, a synthetic cathinone stimulant sometimes sold as a “bath salt” or MDMA-like drug, inactivated CYP2D6 with Ki = 4.2 μM, kinact = 0.069 min-1, and inactivation efficiency = 1.64 x 10-2 min-1 μM-1 — a range the researchers described as comparable to MDMA. Research Highlights CYP2D6 was …
A 2026 Taiwanese case series reported VAS pain drops in all 3 adults treated with pregabalin for type I complex regional pain syndrome: 9 to 5, 2 to 1, and 6 to 3 after doses of 75-150 mg/day. The signal is clinically interesting because pain relief helped rehabilitation participation, but the evidence remains weak because …
A 2026 clinical-lab study tested a 77-drug liquid chromatography-tandem mass spectrometry serum screen in 1,021 patients and found that benzodiazepines accounted for 37.9% of all detections, ahead of antidepressants and antipsychotics.1 Emergency-department cases were a small slice of the sample, but they were positive more often than outpatients: 85.2% vs. 59.5%. Research Highlights Benzodiazepines dominated …
A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …
A 2026 iScience study found that 45 days of clomipramine improved spatial, working, and reference memory in female APP/PS1 Alzheimer’s-model mice, apparently by blocking the E3 ubiquitin ligase Itch rather than by clearing amyloid plaques.1 Research Highlights 45-day clomipramine signal: 6-month female APP/PS1 mice received 25 mg/kg clomipramine every other day for 45 days, then …